Tevogen Bio Holdings Inc. 8-K

What Happened

• On January 30, 2026, Tevogen Bio Holdings Inc. filed a Form 8‑K (Item 7.01, Regulation FD Disclosure) and issued a press release stating the Company's Board of Directors has expressed an intention to evaluate the potential declaration of a one‑time special cash dividend to shareholders.
• The dividend is conditional: it would follow satisfaction of financial milestones that the Board will determine at a future date. The press release is attached as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: January 30, 2026 (Form 8‑K, Item 7.01).
• Action: Board has expressed an intention to evaluate — no dividend has been declared.
• Condition: Any dividend would be contingent on meeting unspecified financial milestones to be set later.
• Disclosure: Press release attached as Exhibit 99.1; no amounts, timing, or milestone specifics provided in the filing.

Why It Matters

• This announcement signals the Board is considering a cash return to shareholders if certain financial goals are met, which could be meaningful to investors seeking near‑term returns.
• Because no dividend has been declared and no details (amount, timing, or milestone criteria) were provided, there is no immediate change to shareholder value or company obligations.
• Investors should watch for future filings or press releases for concrete terms (amount, record date, payment date, and specific milestones) before assuming a payout will occur.